Global Market Direct’s pharmaceuticals report, “Tragara Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Tragara Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Tragara Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Tragara Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Tragara Pharmaceuticals, Inc. - Brief Tragara Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Tragara Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Tragara Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Tragara Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Tragara Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Tragara Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Tragara Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Tragara Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Tragara Pharmaceuticals, Inc. and identify potential opportunities in those areas.
”Chile ENT Devices Investment Opportunities, Analysis and Forecasts to 2018”, a new report by Global Markets Direct, provides key market data on the Chile ENT Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment ... more
Global Markets Direct’s, 'Non-Small Cell Lung Cancer - Pipeline Review, H1 2012', provides an overview of the Non-Small Cell Lung Cancer therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest ... more
Global Markets Direct’s, 'Hemophilia - Pipeline Review, H1 2012', provides an overview of the Hemophilia therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and ... more